Cyfloxan

Moxifloxacin

Bacterial infections eg, acute exacerbations of chronic bronchitis, community acquired pneumonia, acute bacterial sinusitis, complicated skin & skin structure infections, intra-abdominal infections. Mild to moderate pelvic inflammatory disease w/o associated tubo-ovarian or pelvic abscess in combination w/ appropriate antibacterial agent.

Adult ≥18 yr 400 mg once daily. Duration of therapy: Acute exacerbation of chronic bronchitis 5-10 days. Community-acquired pneumonia 10 days. Acute sinusitis 7 days. Skin infections 7-21 days. Intra-abdominal infection 5-14 days. Mild to moderate pelvic inflammatory disease 14 days.

Hypersensitivity to moxifloxacin or other quinolones. History of tendon disease/disorder related to quinolone treatment. Congenital or documented acquired QT prolongation. Electrolyte disturbances eg, hypokalemia. Clinically relevant bradycardia; heart failure w/ reduced left-ventricular ejection fraction. Previous history of symptomatic arrhythmias. Concurrent use w/ other drugs known to prolong QT interval eg, class IA & III, antiarrhythmic agents. Impaired liver function (Child Pugh C); increased transaminases >5x ULN; CrCl <30 mL/min/1.73 m² (serum creatinine >265 μmol/L) or undergoing renal dialysis. Pregnancy & lactation. Patients <18 yr.

Discontinue use at 1st sign of pain or inflammation, cardiac arrhythmia, shock. Not recommended for treatment of MRSA infections, patients w/ complicated pelvic inflammatory disease eg, associated w/ tubo-ovarian or pelvic abscess for whom IV treatment is necessary. Avoid monotherapy w/ pelvic inflammatory disease. Increased risk for ventricular arrhythmias eg, Torsades de pointes. CNS disorders, myasthenia gravis, G6PD deficiency, visual impairment or any effects on the eyes; psychosis or history of psychiatric disease; tendon inflammation & rupture. Pseudomembranous colitis; bullous skin reactions eg, SJS or TEN, sensory or sensorimotor polyneuropathy. Monitor blood glucose. Perform LFTs/investigations. Avoid exposure to UV irradiation or extensive &/or strong sunlight during treatment. Patients for whom Na intake is of medical concern eg, CHF, renal failure, nephrotic syndrome. Concomitant use w/ medication that reduce K & Mg levels. Concurrent use w/ corticosteroids. False -ve Mycobacterium culture test. Galactose intolerance, Lapp-lactase deficiency or glucose-galactose malabsorption. May affect ability to drive & operate machinery. Fulminant hepatitis potentially leading to liver failure. Women. Elderly.

Mycotic superinfections; headache, dizziness; QT prolongation in patients w/ hypokalemia; nausea, vomiting, GI & abdominal pains, diarrhea; increased transaminases.

Impaired absorption w/ antacids eg, Mg or Al hydroxide, didanosine, sucralfate, minerals & multivitamins. Increased risk of ventricular arrhythmias notably Torsades de pointes w/ other drugs known to prolong QT interval eg, anti-arrhythmics class IA eg, quinidine, hydroquinidine, disopyramide or anti-arrhythmics class III eg, amiodarone, sotalol, dofetilide, ibutilide, neuroleptics eg, phenothiazines, pimozide, sertindole, haloperidol, sultopride, TCAs, certain antimicrobials eg, sparfloxacin, erythromycin IV, bepridil, diphemanil. Drug induced-bradycardia or hypokalemia or induced-QT prolongation eg, neuroleptic, certain anti-infective agents eg, some antimalarials, azole antimycotics, macrolides, certain antihistaminics eg, terfenadine, astemizole, cisapride.

Quinolones

J01MA14 - moxifloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.

G